Your browser doesn't support javascript.
loading
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease
Panpan Zhou; Ge Song; Wan-ting He; Nathan Beutler; Longping V. Tse; David R. Martinez; Alexandra Schafer; Fabio Anzanello; Peter Yong; Linghang Peng; Katharina Dueker; Rami Musharrafieh; Sean Callaghan; Tazio Capozzola; Meng Yuan; Hejun Liu; Oliver Limbo; Mara Parren; Elijah Garcia; Stephen A. Rawlings; Davey M. Smith; David Nemazee; Joseph G. Jardine; Ian A. Wilson; Yana Safonova; Thomas Rogers; Ralph S. Baric; Lisa E. Gralinski; Dennis R. Burton; Raiees Andrabi.
Afiliação
  • Panpan Zhou; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Ge Song; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Wan-ting He; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Nathan Beutler; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Longping V. Tse; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • David R. Martinez; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Alexandra Schafer; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Fabio Anzanello; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Peter Yong; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Linghang Peng; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Katharina Dueker; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Rami Musharrafieh; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Sean Callaghan; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Tazio Capozzola; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Meng Yuan; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Hejun Liu; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Oliver Limbo; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
  • Mara Parren; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Elijah Garcia; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Stephen A. Rawlings; Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
  • Davey M. Smith; Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
  • David Nemazee; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Joseph G. Jardine; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
  • Ian A. Wilson; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Yana Safonova; Department of Computer Science, Johns Hopkins University, Baltimore, MD 21218, USA
  • Thomas Rogers; Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
  • Ralph S. Baric; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Lisa E. Gralinski; Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Dennis R. Burton; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Raiees Andrabi; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-479488
ABSTRACT
Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly protective vaccines against coronaviruses that cause severe disease, for anticipating novel pandemic-causing viruses, and to respond more effectively to SARS-CoV-2 variants. The emergence of the Omicron variant of SARS-CoV-2 has illustrated the limitations of solely targeting the receptor binding domain (RBD) of the envelope Spike (S)-protein. Here, we isolated a large panel of broadly neutralizing antibodies (bnAbs) from SARS-CoV-2 recovered-vaccinated donors that target a conserved S2 region in the fusion machinery on betacoronavirus spikes. Select bnAbs show broad in vivo protection against all three pathogenic betacoronaviruses, SARS-CoV-1, SARS-CoV-2 and MERS-CoV, that have spilled over into humans in the past 20 years to cause severe disease. The bnAbs provide new opportunities for antibody-based interventions and key insights for developing pan-betacoronavirus vaccines.
Licença
cc_by_nc_nd
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint